Skip to main content
OSTEOPORE LIMITED logo

OSTEOPORE LIMITED — Investor Relations & Filings

Ticker · OSX ISIN · AU0000053324 ASX Manufacturing
Open in API
Filings indexed 487 across all filing types
Latest filing 2025-03-27 Capital/Financing Update
Country AU Australia
Listing ASX OSX

About OSTEOPORE LIMITED

https://osteopore.com

Osteopore Limited specializes in the design and manufacture of 3D-printed bioresorbable implants. The company utilizes a patented 3D printing process to create scaffolds from bioresorbable polymers, such as polycaprolactone, designed to mimic the natural microstructure of bone. These implants, including the Osteoplug, Osteomesh, and Osteostrip product lines, are applied in neurosurgical, craniofacial, and orthopedic procedures to facilitate bone healing and tissue regeneration. The scaffolds provide a temporary structural framework that supports the body's natural healing process before being gradually absorbed and replaced by the patient's own bone tissue. This technology aims to reduce long-term complications associated with permanent foreign implants by promoting natural tissue integration and restoration across various clinical applications.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - OSX 4 pages 16.7KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed issue of convertible notes by Osteopore Limited. It includes specifics such as the number of securities, issue date, and conditions related to the placement. The content is focused on announcing a capital raising event through a placement of securities. There is no financial performance data, management discussion, or audit information. The document is a formal announcement of a capital/financing activity, consistent with updates on company fundraising or capital structure changes. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length and detail support this classification with high confidence.
2025-03-27 English
OSX opens knee preservation centre of excellence 4 pages 388.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 25 March 2025 from Osteopore Limited. It details the opening of a clinical centre of excellence for a specific medical procedure (medial wedge opening high tibial osteotomy) and discusses partnerships, clinical leadership, market outlook, and product performance. There are no financial statements, regulatory certifications, voting results, or management changes. The content is focused on a corporate update about a clinical initiative and partnership rather than financial results or governance. The document is longer than 5,000 characters and contains substantive information about the company's operational developments. This fits best under a general regulatory announcement category rather than a financial report or management change. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-03-24 English
OSX enhances focus with closure of dental collaboration 3 pages 363.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 20 March 2025 from Osteopore Limited. It discusses the early cessation of a dental grant project and provides updates on the company's strategic refocus, cost management, and financial performance improvements. It references prior ASX announcements and quarterly reports but does not contain detailed financial statements or comprehensive financial data itself. The document is relatively short (5860 characters) and serves as a corporate update rather than a full financial report. It does not fit the criteria for Annual Report, Interim Report, Earnings Release, or other detailed financial filings. It is not a certification or officer attestation. The content is primarily an operational and strategic update communicated via an official stock exchange announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and miscellaneous filings that do not fit other specific categories.
2025-03-19 English
Application for quotation of securities - OSX 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics such as the number of securities, issue dates, and classes of securities. This type of filing is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital change. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive filing about securities quotation.
2025-03-10 English
Investor Presentation 29 pages 18.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Osteopore Limited, containing extensive information about the company's business segments, market opportunities, technology, product examples, and investment highlights. It includes forward-looking statements, market data, and strategic objectives. The text is structured as a presentation with disclaimers, vision, mission, market analysis, and product details. There is no indication that this is a regulatory filing, audit report, earnings release, or official financial report. The content is typical of an investor presentation aimed at providing detailed financial, strategic, and market information to investors. The length (15,000 characters) and detailed content support this classification. Therefore, the document is best classified as an Investor Presentation (IP).
2025-03-03 English
Appendix 4E Preliminary Final Report 14 pages 587.3KB
Annual Report Classification · 95% confidence The document is titled 'Osteopore Limited and Its Controlled Entities Appendix 4E For the year ended 31 December 2024' and contains detailed financial statements including consolidated statements of profit or loss, financial position, changes in equity, and cash flows for the full year ended 31 December 2024. It includes comprehensive financial data, notes on accounting policies, segment reporting, and other disclosures typical of an annual financial report. The length is substantial (15,000 characters), and the content is the report itself, not just an announcement or certification. Appendix 4E is a regulatory filing used in Australia for preliminary final reports, which are annual reports but preliminary. Given the detailed financial statements and the annual period covered, this document fits the definition of an Annual Report (10-K equivalent).
2025-02-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.